March 4, 2016 – Xian and his colleagues studied the effects of tissue plasminogen activator on non-stroke patients.
The DCRI’s Ying Xian, MD, PhD, received a Junior Investigator Award for his presentation at this year’s International Stroke Conference, held last month in Los Angeles.
Xian’s paper, “Use of Intravenous Tissue Plasminogen Activator in Patients without a Stroke (Stroke Mimics): Findings from the Get With The Guidelines Stroke Registry,” examined the use of tissue plasinogen activator (tPA) in “stroke mimics:” non-stroke conditions that present with symptoms similar to stroke. Previous research has shown that tPA improves outcomes in stroke patients, but it must be administered quickly in order to be effective. This increases the likelihood of patients with non-stroke conditions receiving tPA.
Xian and his colleagues analyzed data from the American Heart Association/American Stroke Association Get With The Guidelines Stroke Registry, identifying 90,746 patients treated with tPA between 2009 and 2015. They found that only 728 patients (0.8 percent) received tPA for non-stroke conditions, including migraine (15.6 percent), functional disorder (9.4 percent), and seizure (7.2 percent). Rates of symptomatic intracranial hemorrhage were quite rare in stroke mimic patients (0.4 percent) compared to patients with an ischemic stroke (4.3 percent).
Despite the low number of patients who received tPA for non-stroke conditions, Xian and his colleagues concluded that there are opportunities to continue to improve the rapid and accurate diagnosis and treatment of ischemic stroke.
The study’s other DCRI authors included Adrian Hernandez, MD, MHS; Andrzej Kosinksi, PhD; Janet Prvu Bettger, ScD; Barbara Lytle, MS; and Eric Peterson, MD, MPH.